Skip to main content
OpenTrials
Completed

NCT Number: NCT02328599

Alliance of Randomized Trials of Medicine vs Metabolic Surgery in Type 2 Diabetes

Initially, 4 teams of investigators conducted randomized controlled trials (RCT) at their own site to evaluate the effectiveness of bariatric surgery compared to medical/lifestyle management of type 2 diabetes. Each study followed subjects for a duration of about 1 - 3 years. Following this, a consortium was created to pool data and continue to follow study participants. This early collaboration of the 4 groups of investigators was supported by Industry sponsors (Ethicon, Inc and Medtronic-MITG). Now, the investigators have successfully received a grant from the NIH, as the sole supporter of continued observational follow-up of study participants.

The continuing aim of this study is to combine data from the 4 studies and follow the original randomized subjects for an additional 5 years of follow-up. The purpose of the study is to determine the longer term durability and effectiveness of bariatric surgery compared to medical/lifestyle intervention on the treatment of type 2 diabetes.

Completed

Looking for future studies?

Notify Me

Key information

Age range

20 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Joslin Diabetes Center, Boston, Massachusetts, United States

Loading trial locations.

About this study

The four investigative groups initiated their individual RCT's at their respective sites to evaluate the effectiveness of bariatric surgery compared to multidisciplinary medical and lifestyle management of diabetes and body weight. The original trials were each designed to assess feasibility over a relatively short duration of follow-up (1-3 years). Individually, each trial lacked the sample size and duration of follow-up to meaningfully inform clinical decision making. Together, with the funding provided by the NIH for longer follow-up, the Consortium trial can provide a unique national resource to address timely and unanswered clinical questions related to the durability of these alternative management approaches in patients with T2D and obesity. Together, participants from these studies represent the largest cohort with diabetes (one third having a BMI <35 kg/m2) ever to undergo randomized assignment to bariatric surgical procedure vs. medical/lifestyle intervention.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Original inclusion criteria for participation in the RCTs at all sites included:
  • Candidate for general anesthesia or unsupervised exercise.
  • Age ≥20 and ≤65 years.
  • Body mass index >27 and ≤45 kg/m2.
  • Diagnosis of type 2 diabetes confirmed by either requiring diabetes medication and/or having elevated glycemia based on HbA1c, fasting plasma glucose, and/or oral glucose tolerance test (OGTT) results, according to American Diabetes Association criteria.
  • Ability and willingness to participate in the study and agree to any of the research arms.
  • Able to understand the options and to comply with the requirements of each program.
  • Negative urine pregnancy test at screening and baseline visits (prior to surgery) for women of childbearing potential (i.e., biologically capable of becoming pregnant).

Exclusion criteria

  • Subjects who were randomized in one of the four RCTs but never initiated intervention / did not receive randomized treatment
  • Refusal to sign informed consent

Treatment and study plan

Bariatric surgery involving Roux-en-Y gastric bypass

Procedure

Subjects previously underwent Bariatric surgery involving Roux-en-Y gastric bypass (RYGB) surgery at one of the 4 participating sites and will be followed prospectively.

Other names: RYGB

Bariatric surgery involving Laparoscopic adjustable gastric banding

Procedure

Subjects previously underwent Bariatric surgery involving laparoscopic adjustable gastric banding (LAGB) surgery at one of the 4 participating sites and will be followed prospectively.

Other names: LAGB

Bariatric surgery involving Laparoscopic sleeve gastrectomy

Procedure

Subjects previously underwent Bariatric surgery involving laparoscopic sleeve gastrectomy (LSG) surgery at one of the 4 participating sites and will be followed prospectively.

Other names: LSG

Primary outcomes

  1. Change in HbA1c

    Time frame: 7 years and up to 13 years for earliest enrollees

    Between group (medical vs. surgical) in HbA1c from baseline to 7 year for all participants and up to 13 years for the earliest enrollees

Secondary outcomes

  1. HbA1c < 6.5%

    Time frame: 7 years and each annual visit through the last known follow-up for all patients up to 13 years

    percent of those achieving diabetes remission without the need for anti-diabetic medications

Other outcomes

  1. HbA1c >6.5%

    Time frame: 7-13 years

    relapse in diabetes control requiring the addition of anti-diabetic medications

  2. change in body weight measured in BMI

    Time frame: 7 years and up to 13 years for earliest enrollees

    Change in body weight status from baseline

  3. change in fasting glucose

    Time frame: 7 years and up to 13 years for earliest enrollees

    Change in diabetes related outcomes including cardiovascular risk factors

  4. change in cholesterol levels

    Time frame: 7 years and up to 13 years for earliest enrollees

    Change in diabetes related outcomes including cardiovascular risk factors

  5. change in blood pressure

    Time frame: 7 years and up to 13 years for earliest enrollees

    Change in diabetes related outcomes including cardiovascular risk factors

  6. change in albuminuria

    Time frame: 7 years and up to 13 years for earliest enrollees

    Change in diabetes related outcomes including cardiovascular risk factors

Sponsors and collaborators

Lead sponsor

Ali Aminian

Other

Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
  • The Cleveland Clinic

Registry information

Official study title

A Prospective Consortium Evaluating the Long-term Follow-up of Patients With Type 2 Diabetes Enrolled In a Randomized Controlled Trial Comparing Bariatric Surgery Versus Medical Management

Acronym: ARMMS-T2D

Important dates

Study start
2018
Primary completion
2024
Study completion
2024
First posted
Dec 31, 2014
Registry last updated
Mar 31, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.